OR10H1 Inhibitors
OR10H1 inhibitors encompass a variety of compounds that affect the signaling pathways in which OR10H1 is involved, ultimately leading to its decreased function. The chemical GDP-beta-S is an effective tool in this regard, as it binds to G-proteins associated with OR10H1, preventing the necessary GTP exchange for G-protein activation, which is a pivotal step in OR10H1 signal transduction. Similarly, pertussis toxin modifies the Gi/Go proteins via ADP-ribosylation, disrupting their interaction with OR10H1 and the subsequent inhibitory signaling that would normally temper adenylate cyclase activity, thereby indirectly decreasing OR10H1 signaling.
Adenylyl cyclase plays a central role in OR10H1 signaling by producing cAMP, and its inhibition by compounds such as SQ22536 leads to a direct reduction in OR10H1 signal output. In contrast, forskolin's activation of adenylyl cyclase increases cAMP levels, which paradoxically leads to OR10H1 desensitization and downregulation over time. Phospholipase C, which produces IP3 and DAG, is another key enzyme in OR10H1-associated pathways; its inhibition by U73122 results in diminished OR10H1 activity. Protein kinase C, targeted by Go 6983 and chelerythrine, is integral to phosphorylation events downstream of OR10H1 activation, and its inhibition consequently reduces OR10H1 signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
Pertussis toxin ADP-ribosylates the Gi/Go proteins, preventing their interaction with OR10H1 and effectively blocking the inhibitory G-protein signaling pathway that would dampen adenylate cyclase activity, indirectly leading to decreased OR10H1 function. | ||||||
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $93.00 $356.00 | 13 | |
SQ22536 acts as an adenylyl cyclase inhibitor, reducing the production of cAMP from ATP, which is a key second messenger in the OR10H1 signaling cascade, leading to a reduction in OR10H1 signaling output. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin increases cAMP levels by activating adenylyl cyclase, which can lead to OR10H1 desensitization through chronic activation and potential downregulation, decreasing its function. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Go 6983 inhibits protein kinase C, which is involved in phosphorylation events downstream of OR10H1 activation, thereby reducing the OR10H1 signaling cascade. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a PKC inhibitor that prevents the phosphorylation of proteins within the OR10H1 signaling pathway, thus reducing OR10H1 functional activity. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $97.00 $144.00 $648.00 | 47 | |
KT5720 inhibits protein kinase A, which is involved in phosphorylating target proteins in the OR10H1 signaling pathway, thereby decreasing OR10H1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3 kinase, affecting the PI3K/Akt pathway and indirectly reducing OR10H1 signaling by altering the cellular context in which OR10H1 operates. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that may reduce OR10H1 activity by altering the phosphorylation state of proteins within OR10H1-associated pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an MEK inhibitor that prevents activation of the MAPK/ERK pathway, reducing the downstream effects that could enhance OR10H1 activity, thus leading to decreased OR10H1 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK, which is involved in signaling pathways where p38 MAPK is a downstream effector, affecting the activity of OR10H1 in these pathways. | ||||||